Acta Dermato-Venereologica (Mar 2019)

Clinical Profile of Methotrexate-resistant Juvenile Localised Scleroderma

  • Juliette Hardy,
  • Franck Boralevi,
  • Stéphanie Mallet,
  • Natalia Cabrera,
  • Alexandre Belot,
  • Alice Phan,
  • Sébastien Barbarot,
  • Audrey Duriez-Lasek,
  • Christine Chiaverini,
  • Thomas Hubiche,
  • Emmanuel Mahé,
  • Edouard Bégon,
  • Emmanuelle Bourrat,
  • Olivia Boccara,
  • Hélène Aubert,
  • Martine Grall Lerosey,
  • Catherine Droitcourt,
  • Maryam Piram,
  • Juliette Mazereeuw-Hautier,
  • Research Group of the French Society of Paediatric Dermatology (SDFP in French)

DOI
https://doi.org/10.2340/00015555-3155
Journal volume & issue
Vol. 99, no. 6
pp. 539 – 543

Abstract

Read online

Methotrexate has demonstrated its efficiency for the treatment of juvenile localized scleroderma but some patients may be resistant. The aim of our study was to define the profile of such patients. We performed an observational retrospective multicenter study between 2007 and 2016 and included all children seen in the French Paediatric Dermatology and Rheumatology departments with active localized scleroderma treated by methotrexate for a minimum of 4 months. Metho­trexate efficacy was assessed clinically and/or by imaging between the fourth to twelfth months of treatment. A total of 57 patients were included. Metho­trexate dosage ranged from 7 to 15 mg/m2/week. Only 4 patients were resistant. No common features could be identified between these 4 patients. Children with localized scleroderma are rarely resistant to metho­trexate and we did not identify a clinical profile for those resistant patients.

Keywords